{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T11:06:56Z","timestamp":1785582416644,"version":"3.56.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005088","name":"Beijing Municipal Health Commission","doi-asserted-by":"publisher","award":["CFH2024-2-2175"],"award-info":[{"award-number":["CFH2024-2-2175"]}],"id":[{"id":"10.13039\/501100005088","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002799","name":"Capital Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002799","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virologica Sinica"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.virs.2025.10.003","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:47:09Z","timestamp":1761007629000},"page":"835-841","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of switching from lopinavir\/ritonavir-based regimens to bictegravir\/emtricitabine\/tenofovir alafenamide in people living with HIV: A multicenter retrospective study"],"prefix":"10.1016","volume":"40","author":[{"given":"Jiantao","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxiang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongxing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinchuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingyan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6410-7490","authenticated-orcid":false,"given":"Jianhua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2450-4830","authenticated-orcid":false,"given":"Lijun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7856-2877","authenticated-orcid":false,"given":"Hongxin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virs.2025.10.003_bib1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1473-3099(19)30036-2","article-title":"Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (dawning): an open-label, non-inferiority, phase 3b trial","volume":"19","author":"Aboud","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.virs.2025.10.003_bib2","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/jac\/dkab481","article-title":"Real-life experience with bictegravir\/emtricitabine\/tenofovir alafenamide in a large reference clinical centre","volume":"77","author":"Ambrosioni","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.virs.2025.10.003_bib3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(14)70782-0","volume":"14","author":"Arribas","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.virs.2025.10.003_bib4","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/S0140-6736(13)61164-2","volume":"381","author":"Boyd","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.virs.2025.10.003_bib5","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/S2352-3018(16)30189-8","volume":"4","author":"Boyd","year":"2017","journal-title":"Lancet HIV"},{"key":"10.1016\/j.virs.2025.10.003_bib6","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(98)03391-1","article-title":"Pathogenesis of hiv-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance","volume":"351","author":"Carr","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.virs.2025.10.003_bib7","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","article-title":"Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study","volume":"353","author":"Carr","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.virs.2025.10.003_bib8","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.2147\/IDR.S331647","article-title":"Outcomes after switching to BIC\/FTC\/TAF in patients with virological failure to protease inhibitors or non-nucleoside reverse transcriptase inhibitors: a real-world cohort study","volume":"14","author":"Chang","year":"2021","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.virs.2025.10.003_bib9","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.2165\/11204950-000000000-00000","article-title":"Lopinavir\/ritonavir: a review of its use in the management of HIV-1 infection","volume":"70","author":"Croxtall","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.virs.2025.10.003_bib10","doi-asserted-by":"crossref","first-page":"e436","DOI":"10.1016\/S2352-3018(24)00089-4","volume":"11","year":"2024","journal-title":"Lancet HIV"},{"key":"10.1016\/j.virs.2025.10.003_bib11","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1016\/S2352-3018(18)30091-2","volume":"5","author":"Daar","year":"2018","journal-title":"Lancet HIV"},{"key":"10.1016\/j.virs.2025.10.003_bib12","first-page":"990","article-title":"Weight, anthropometric and metabolic changes after discontinuing antiretroviral therapy containing tenofovir alafenamide in people with HIV","volume":"79","author":"Damas","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.virs.2025.10.003_bib13","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s40265-018-1010-7","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide: a review in hiv-1 infection","volume":"78","author":"Deeks","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.virs.2025.10.003_bib14","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0140-6736(09)62041-9","article-title":"Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (switchmrk 1 and 2): two multicentre, double-blin, randomised controlled trials","volume":"375","author":"Eron","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.virs.2025.10.003_bib15","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1097\/QAD.0000000000001675","article-title":"Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk","volume":"31","author":"Gatell","year":"2017","journal-title":"Aids"},{"key":"10.1016\/j.virs.2025.10.003_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1473-3099(17)30630-8","article-title":"Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial","volume":"18","author":"Hakim","year":"2018","journal-title":"Lancet Infect. Dis."},{"issue":"Suppl. 2","key":"10.1016\/j.virs.2025.10.003_bib17","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1093\/infdis\/jit107","article-title":"Emergence of hiv drug resistance during first- and second-line antiretroviral therapy in resource-limited settings","volume":"207","author":"Hosseinipour","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virs.2025.10.003_bib18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/QAD.0b013e32833f9d02","article-title":"European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS clinical trials group study A5142","volume":"25","author":"Hulgan","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.virs.2025.10.003_bib19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3851\/IMP1719","article-title":"Virological characterization of patients failing darunavir\/ritonavir or lopinavir\/ritonavir treatment in the artemis study: 96-week analysis","volume":"16","author":"Lathouwers","year":"2011","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.virs.2025.10.003_bib20","doi-asserted-by":"crossref","first-page":"9866","DOI":"10.3390\/ijms23179866","article-title":"The mechanism-based inactivation of CYP3A4 by ritonavir: what mechanism?","volume":"23","author":"Loos","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.virs.2025.10.003_bib21","doi-asserted-by":"crossref","first-page":"e652","DOI":"10.1093\/cid\/ciac621","article-title":"Metabolic-related outcomes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in adults with human immunodeficiency virus (HIV): a multicenter prospective cohort study","volume":"76","author":"Mart\u00ednez-Sanz","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.virs.2025.10.003_bib22","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.virs.2025.10.003_bib23","series-title":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV","year":"2025"},{"key":"10.1016\/j.virs.2025.10.003_bib24","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurjpc\/zwad330","article-title":"Impact of hypertriglyceridaemia on cardiovascular mortality according to low-density lipoprotein cholesterol in a 15.6-million population","volume":"31","author":"Park","year":"2024","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.virs.2025.10.003_bib25","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/S2352-3018(17)30065-6","article-title":"Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, earnest trial","volume":"4","author":"Paton","year":"2017","journal-title":"Lancet HIV"},{"key":"10.1016\/j.virs.2025.10.003_bib26","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1016\/S2352-3018(22)00092-3","volume":"9","author":"Paton","year":"2022","journal-title":"Lancet HIV"},{"key":"10.1016\/j.virs.2025.10.003_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101991","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials","volume":"59","author":"Sax","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.virs.2025.10.003_bib28","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1097\/QAD.0b013e3282742000","article-title":"Virological failure and subsequent resistance profiles in individuals exposed to atazanavir","volume":"21","author":"Stebbing","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.virs.2025.10.003_bib29","doi-asserted-by":"crossref","first-page":"758","DOI":"10.7326\/M20-4853","article-title":"Weight and metabolic changes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV: a cohort study","volume":"174","author":"Surial","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.virs.2025.10.003_bib30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijid.2022.11.012","article-title":"Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N\/R mutation","volume":"126","author":"Tsai","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.virs.2025.10.003_bib31","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/jmv.22189","article-title":"Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa","volume":"83","author":"van Zyl","year":"2011","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.virs.2025.10.003_bib32","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/cid\/ciae012","volume":"79","author":"Wang","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.virs.2025.10.003_bib33","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1097\/CM9.0000000000003330","article-title":"Human immunodeficiency virus\/acquired immune deficiency syndrome antiretroviral therapy initiated on the same day in treatment-na\u00efve people with human immunodeficiency virus: a comparative study of efficacy and regimen","volume":"137","author":"Yuan","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.virs.2025.10.003_bib34","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/hiv.13020","article-title":"Characteristics and viral suppression among people living with HIV from the national free antiretroviral therapy programme, 2019","volume":"21","author":"Zhao","year":"2020","journal-title":"HIV Med."},{"key":"10.1016\/j.virs.2025.10.003_bib35","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/cid\/ciu367","article-title":"Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens","volume":"59","author":"Zheng","year":"2014","journal-title":"Clin. Infect. Dis."}],"container-title":["Virologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1995820X25001397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1995820X25001397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:05:29Z","timestamp":1773291929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1995820X25001397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1995820X25001397"],"URL":"https:\/\/doi.org\/10.1016\/j.virs.2025.10.003","relation":{},"ISSN":["1995-820X"],"issn-type":[{"value":"1995-820X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of switching from lopinavir\/ritonavir-based regimens to bictegravir\/emtricitabine\/tenofovir alafenamide in people living with HIV: A multicenter retrospective study","name":"articletitle","label":"Article Title"},{"value":"Virologica Sinica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virs.2025.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd\u00e9","name":"copyright","label":"Copyright"}]}}